Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMTX
#4421
Immatics N.V. - Ordinary Shares
0.1
2
USD
-98.99%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-98.99%
Monthly Change
-98.98%
6 month change
-98.90%
Year Change
-98.89%
Previous Close
11.4
5
Open
0.1
2
Low
0.1
1
High
0.1
2
Volume
34
Markets
US Stock Market
Healthcare
IMTX
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
62.91 M
62.93 M
76.67 M
84.66 M
121.55 M
134.07 M
134.07 M
Valuation ratios
Enterprise value
678.78 M
845.74 M
657.07 M
907.53 M
864.22 M
1.41 B
1.51 B
Price to earnings ratio
—
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
—
News
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
NVO Q1 Earnings & Sales Top Estimates, 2026 Outlook Raised, Stock Up
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)
Immatics NV earnings beat by €0.13, revenue topped estimates
Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates